MedDataX Logo

Taining Golden Lake Comprehensive Chronic Disease Management Initiative

NCT ID: NCT07308314

Last Updated: 2025-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-01

Study Completion Date

2028-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to establish the first county-level, population-based prospective cohort in Taining County, Fujian Province, China. The cohort will include at least 20,000 residents aged 18 years or older. The project will systematically collect questionnaires, physical measurements, laboratory tests, imaging data, and biological samples to build a multi-dimensional health database and biobank. Through 3-year follow-up, the study seeks to reveal the epidemiological patterns and risk factors of chronic diseases, characterize the natural course of multimorbidity and aging syndromes, and develop a comprehensive chronic disease management model suitable for rural and mountainous regions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

China is undergoing rapid population aging, with chronic non-communicable diseases (NCDs) becoming the leading cause of death and disability. Taining County, located in a mountainous area of Fujian Province, faces a higher-than-average aging population and a growing burden of hypertension, diabetes, dyslipidemia, and cardiovascular diseases. Early detection and standardized management remain insufficient, and healthcare resources are limited. This study will establish a prospective cohort covering ≥20,000 residents, integrating demographic, lifestyle, clinical, laboratory, and imaging data. Active follow-up will be conducted annually, complemented by passive follow-up through local healthcare and death registry systems. The study will (1) identify epidemiological features and risk factors of common chronic diseases, (2) explore multimorbidity and aging trajectories, and (3) develop a replicable "Taining Model" for chronic disease prevention and management at the county level. The results will provide an evidence base for public health decision-making and chronic disease control strategies in similar rural and mountainous regions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Disease Chronic Disease Management Hypertension Diabetes Mellitus Dyslipidemias Frailty Sarcopenia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Chronic Disease Management Prospective Cohort Hypertension Diabetes Mellitus Dyslipidemia Cardiovascular Disease Frailty Sarcopenia Aging Healthy Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Taining County Resident Cohort

A community-based cohort of ≥20,000 adult residents (aged 18 years and older) living in Taining County, Fujian Province, China. Participants will undergo baseline assessments including questionnaires, physical examinations, laboratory tests, imaging, and biospecimen collection. Annual follow-up (active and passive) will be conducted for 3 years to record incidence of chronic diseases, functional status, and aging-related outcomes.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years, male or female.
* Resident of Taining County for ≥6 months and expected to remain in the county for at least the next 3 years.
* Full civil capacity and able to understand study procedures.
* Willing to voluntarily participate and provide written informed consent.
* Able to complete baseline survey and follow-up visits.

Exclusion Criteria

* Refusal to sign informed consent.
* Severe psychiatric disorders or cognitive impairment preventing participation.
* End-stage disease with expected survival \<1 year.
* Long-term migrants (≥6 months per year outside the county), unable to guarantee follow-up.
* Participation in other clinical studies that may interfere with this research.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

First Affiliated Hospital of Fujian Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dajun Chai

Professor and Chief Physician, Department of Cardiology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dajun Chai, MD

Role: PRINCIPAL_INVESTIGATOR

First Affiliated Hospital of Fujian Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dajun Chai, MD

Role: CONTACT

Phone: 0086059187981637

Email: [email protected]

Hailin Zhang

Role: CONTACT

Phone: 0086059187981637

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hailin Zhang

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Chen L, Li X, Lv Y, Tan X, Zhong VW, Rong S, Liu G, Liu L. Physical frailty, adherence to ideal cardiovascular health and risk of cardiovascular disease: a prospective cohort study. Age Ageing. 2023 Jan 8;52(1):afac311. doi: 10.1093/ageing/afac311.

Reference Type BACKGROUND
PMID: 36626327 (View on PubMed)

Hu L, Li J, Tang Z, Gong P, Chang Z, Yang C, Ma T, Jiang S, Yang C, Zhang T. How does biological age acceleration mediate the associations of obesity with cardiovascular disease? Evidence from international multi-cohort studies. Cardiovasc Diabetol. 2025 May 14;24(1):209. doi: 10.1186/s12933-025-02770-0.

Reference Type BACKGROUND
PMID: 40369582 (View on PubMed)

Global Cardiovascular Risk Consortium; Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, Aviles-Santa L, De Bacquer D, Ballantyne CM, Bernabe-Ortiz A, Bobak M, Brenner H, Carrillo-Larco RM, de Lemos J, Dobson A, Dorr M, Donfrancesco C, Drygas W, Dullaart RP, Engstrom G, Ferrario MM, Ferrieres J, de Gaetano G, Goldbourt U, Gonzalez C, Grassi G, Hodge AM, Hveem K, Iacoviello L, Ikram MK, Irazola V, Jobe M, Jousilahti P, Kaleebu P, Kavousi M, Kee F, Khalili D, Koenig W, Kontsevaya A, Kuulasmaa K, Lackner KJ, Leistner DM, Lind L, Linneberg A, Lorenz T, Lyngbakken MN, Malekzadeh R, Malyutina S, Mathiesen EB, Melander O, Metspalu A, Miranda JJ, Moitry M, Mugisha J, Nalini M, Nambi V, Ninomiya T, Oppermann K, d'Orsi E, Pajak A, Palmieri L, Panagiotakos D, Perianayagam A, Peters A, Poustchi H, Prentice AM, Prescott E, Riserus U, Salomaa V, Sans S, Sakata S, Schottker B, Schutte AE, Sepanlou SG, Sharma SK, Shaw JE, Simons LA, Soderberg S, Tamosiunas A, Thorand B, Tunstall-Pedoe H, Twerenbold R, Vanuzzo D, Veronesi G, Waibel J, Wannamethee SG, Watanabe M, Wild PS, Yao Y, Zeng Y, Ziegler A, Blankenberg S. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med. 2023 Oct 5;389(14):1273-1285. doi: 10.1056/NEJMoa2206916. Epub 2023 Aug 26.

Reference Type BACKGROUND
PMID: 37632466 (View on PubMed)

Moturi S, Ghosh-Choudhary SK, Finkel T. Cardiovascular disease and the biology of aging. J Mol Cell Cardiol. 2022 Jun;167:109-117. doi: 10.1016/j.yjmcc.2022.04.005. Epub 2022 Apr 11.

Reference Type BACKGROUND
PMID: 35421400 (View on PubMed)

Liberale L, Badimon L, Montecucco F, Luscher TF, Libby P, Camici GG. Inflammation, Aging, and Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2022 Mar 1;79(8):837-847. doi: 10.1016/j.jacc.2021.12.017.

Reference Type BACKGROUND
PMID: 35210039 (View on PubMed)

Hu C. Prevention of cardiovascular disease for healthy aging and longevity: A new scoring system and related "mechanisms-hallmarks-biomarkers". Ageing Res Rev. 2025 May;107:102727. doi: 10.1016/j.arr.2025.102727. Epub 2025 Mar 15.

Reference Type BACKGROUND
PMID: 40096912 (View on PubMed)

da Silva PFL, Schumacher B. Principles of the Molecular and Cellular Mechanisms of Aging. J Invest Dermatol. 2021 Apr;141(4S):951-960. doi: 10.1016/j.jid.2020.11.018. Epub 2021 Jan 29.

Reference Type BACKGROUND
PMID: 33518357 (View on PubMed)

Moqri M, Herzog C, Poganik JR; Biomarkers of Aging Consortium; Justice J, Belsky DW, Higgins-Chen A, Moskalev A, Fuellen G, Cohen AA, Bautmans I, Widschwendter M, Ding J, Fleming A, Mannick J, Han JJ, Zhavoronkov A, Barzilai N, Kaeberlein M, Cummings S, Kennedy BK, Ferrucci L, Horvath S, Verdin E, Maier AB, Snyder MP, Sebastiano V, Gladyshev VN. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023 Aug 31;186(18):3758-3775. doi: 10.1016/j.cell.2023.08.003.

Reference Type BACKGROUND
PMID: 37657418 (View on PubMed)

Nash DB. The Future of Chronic Disease Management. Popul Health Manag. 2023 Aug;26(S1):S2-S3. doi: 10.1089/pop.2023.0128. No abstract available.

Reference Type BACKGROUND
PMID: 37603800 (View on PubMed)

Elendu C, Elendu RC, Enyong JM, Ibhiedu JO, Ishola IV, Egbunu EO, Meribole ES, Lawal SO, Okenwa CJ, Okafor GC, Umeh ED, Mutalib OO, Opashola KA, Fatoye JO, Awotoye TI, Tobih-Ojeanelo JI, Ramon-Yusuf HI, Olanrewaju A, Afuh RN, Adenikinju J, Amosu O, Yusuf A. Comprehensive review of current management guidelines of chronic kidney disease. Medicine (Baltimore). 2023 Jun 9;102(23):e33984. doi: 10.1097/MD.0000000000033984.

Reference Type BACKGROUND
PMID: 37335639 (View on PubMed)

Chan SW. Chronic Disease Management, Self-Efficacy and Quality of Life. J Nurs Res. 2021 Feb 1;29(1):e129. doi: 10.1097/JNR.0000000000000422. No abstract available.

Reference Type BACKGROUND
PMID: 33427791 (View on PubMed)

Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, Agusti AA, Vogelmeier CF. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021 Jan 1;203(1):24-36. doi: 10.1164/rccm.202009-3533SO.

Reference Type BACKGROUND
PMID: 33146552 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MRCTA,ECFAH of FMU[2025]950

Identifier Type: -

Identifier Source: org_study_id